Notably, USP14 knockdown upregulates cytotoxic T-cell activity and enhances anti-tumor immunity in CRC by downregulating IDO1 expression without affecting AhR activity, suggesting a potential avenue for CRC-targeted therapy [98]. The gene discussed is AHR; the disease is neoplasm.